Author’s response to reviews

Title: Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

Authors:

Arata Nakajima (a-nakaji@sf7.so-net.ne.jp)
Keiichiro Terayama (kei-tera@sakura.med.toho-u.ac.jp)
Masato Sonobe (masato0609@aol.com)
Yasuchika Aoki (yasuaoki35@sf4.so-net.ne.jp)
Hiroshi Takahashi (hiroshi.takahashi@med.toho-u.ac.jp)
Yorikazu Akatsu (yorikazu.akatsu@med.toho-u.ac.jp)
Junya Saito (junya.saito@med.toho-u.ac.jp)
Shinji Taniguchi (shinji.taniguchi@med.toho-u.ac.jp)
Manabu Yamada (manabu.yamada@med.toho-u.ac.jp)
Ayako Kubota (ayakokubota@med.toho-u.ac.jp)
Koichi Nakagawa (konakag@med.toho-u.ac.jp)

Version: 3 Date: 21 Sep 2019

Author’s response to reviews:

Thank you for the review of our manuscript. We have revised our manuscript according to the points raised by the reviewers. Below are our responses to the points by the reviewers.

1. Please remove the Author Contributions from the “Funding” section of your declarations.

Response: We have removed the Author Contributions from the “Funding” section of our declarations.

2. In the “Funding” section of your declarations, please clarify the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Response: In the “Funding” section of our declarations, we have stated that the fund was used for the measurement and analysis of the serum levels of ROM.

3. We note that the current submission contains some textual overlap with other previously published works, in particular:

Lines 81-88, 119-121, 131-133, 268-272:


Lines 122-127:


While we understand that you may wish to express some of the same ideas contained in these publications, please be aware that we cannot condone the use of text from previously published work, works even if the authors of the work are yourselves.

If there is overlap in the Methods section, please ensure to summarize the methods and cite the source.

Please re-phrase these sections to minimise overlap.

Response: We have summarized the introduction and methods to minimize the overlap with our previous publications pointed by the reviewers.

4. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Response: We have uploaded the final, clean version.